<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology of and immune response to Helicobacter pylori infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology of and immune response to Helicobacter pylori infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology of and immune response to Helicobacter pylori infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Helicobacter pylori</em> (<em>H. pylori</em>) is highly adapted to the gastric environment where it lives within or beneath the gastric mucous layer (see  <a class="medical medical_review" href="/d/html/16.html" rel="external">"Bacteriology and epidemiology of Helicobacter pylori infection"</a>). The bacterium generally does not invade gastroduodenal tissue. Instead, it renders the underlying mucosa more vulnerable to acid peptic damage by disrupting the mucous layer, liberating enzymes and toxins, and adhering to the gastric epithelium. In addition, the host immune response to <em>H. pylori</em> incites an inflammatory reaction which further perpetuates tissue injury.</p><p>The chronic inflammation induced by <em>H. pylori </em>upsets gastric acid secretory physiology to varying degrees and leads to chronic gastritis which, in most individuals is asymptomatic and does not progress (<a class="graphic graphic_picture graphicRef63916" href="/d/graphic/63916.html" rel="external">picture 1</a>). In some cases, however, altered gastric secretion coupled with tissue injury leads to peptic ulcer disease, while in other cases, gastritis progresses to atrophy, intestinal metaplasia, and eventually gastric carcinoma or rarely, due to persistent immune stimulation of gastric lymphoid tissue, gastric lymphoma. (See  <a class="medical medical_review" href="/d/html/17.html" rel="external">"Association between Helicobacter pylori infection and duodenal ulcer"</a> and  <a class="medical medical_review" href="/d/html/31.html" rel="external">"Acute and chronic gastritis due to Helicobacter pylori"</a> and  <a class="medical medical_review" href="/d/html/16636.html" rel="external">"Gastric intestinal metaplasia"</a> and  <a class="medical medical_review" href="/d/html/30.html" rel="external">"Metaplastic (chronic) atrophic gastritis"</a> and  <a class="medical medical_review" href="/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p>As a result, the pathophysiology of <em>H. pylori </em>infection and its eventual clinical outcome should be viewed as a complex interaction between the host and the bacterium. This interaction is influenced by the environment and modulated by a number of largely as yet unidentified factors [<a href="#rid1">1,2</a>].</p><p>The pathophysiology of <em>H. pylori</em> infection as it relates to gastrointestinal disease in general will be reviewed here. The role of <em>H. pylori</em> in specific disease processes is discussed separately. (See  <a class="medical medical_review" href="/d/html/17.html" rel="external">"Association between Helicobacter pylori infection and duodenal ulcer"</a> and  <a class="medical medical_review" href="/d/html/31.html" rel="external">"Acute and chronic gastritis due to Helicobacter pylori"</a> and  <a class="medical medical_review" href="/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BACTERIAL FACTORS</span><span class="headingEndMark"> — </span>Tissue injury induced by <em>H. pylori</em> depends upon bacterial attachment and the subsequent release of enzymes and other microbial products that can cause cellular damage.</p><p class="headingAnchor" id="H3"><span class="h2">Bacterial attachment</span><span class="headingEndMark"> — </span><em>H. pylori</em> <strong>exclusively</strong> colonizes gastric type epithelium, which suggests specific recognition of cell type by the bacterium [<a href="#rid3">3</a>]. Electron microscopy has confirmed the presence of tight adherence of <em>H. pylori</em> to the gastric cell surface through formation of membrane attachment pedestals similar to those described with enteropathogenic Escherichia coli [<a href="#rid4">4,5</a>]. This process requires that bacterial adhesins recognize and specifically bind to host receptors expressed on the cell surface [<a href="#rid3">3</a>]. The attachment process may morphologically or functionally alter the epithelial cell or activate certain bacterial functions making them more toxic. At the site of adherence, bacterial membrane proteins coded by genes contained in the cag pathogenicity island (PAI) open channels in the epithelial cell membrane that enable direct contact of bacterial factors with the cytoplasm [<a href="#rid6">6</a>].</p><p>Bacterial attachment is partially mediated by a number of adhesins and outer membrane proteins. Three Hop proteins have been implicated in the pathogenesis of <em>H. pylori</em> infection, BabA (HopS), OipA (HopH), and SabA (HopP) [<a href="#rid7">7</a>]. BabA, the best characterized of the three adhesin proteins, mediates binding to fucosylated Lewis b (Le(b)) blood group antigens on host cells [<a href="#rid8">8</a>]. OipA may serve as an adhesin but it also promotes inflammation by increasing IL-8 expression [<a href="#rid9">9</a>]. SabA mediates binding to glycoconjugates containing sialic acid [<a href="#rid10">10</a>]. Replacement of nonsialylated Lewis antigens by sialylated Le(x) or Le(a) has been associated with <em>H. pylori</em> induced gastric inflammation and cancer [<a href="#rid10">10,11</a>]. Thus, the role of Lewis antigen expression in bacterial attachment is unclear. Nevertheless, the homologous structures of <em>H. pylori</em> lipopolysaccharide and host LewisX antigen may lead to an autoimmune response with subsequent cell injury [<a href="#rid12">12,13</a>]. <em>H. pylori</em> can also bind to class II MHC molecules on the surface of gastric epithelial cells and induce apoptosis [<a href="#rid14">14</a>]. In fact, binding of the organism's urease to surface class II MHC is itself sufficient to induce apoptosis [<a href="#rid15">15</a>]. <em>H. pylori</em> modifies its lipid A in the outer membrane by removal of phosphate groups from the 1- and 4'-positions of the lipid A backbone. The enzyme responsible for dephosphorylation of the lipid A 4'-phosphate group in <em>H. pylori</em>, Jhp1487 (LpxF), has been identified and mutants created to demonstrate that dephosphorylation of the lipid A domain of <em>H. pylori</em> LPS by LpxE and LpxF is key to its ability to colonize the mammalian host [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Release of enzymes</span><span class="headingEndMark"> — </span><em>H. pylori</em> elaborates several enzymes that can cause cellular damage by direct or indirect mechanisms.</p><p class="bulletIndent1"><span class="glyph">●</span>Urease accounts for over 5 percent of the organism's total protein weight [<a href="#rid17">17</a>]. Urea, when hydrolyzed by bacterial urease, can form compounds such as ammonium chloride and monochloramine that can directly damage epithelial cells [<a href="#rid18">18</a>]. In addition, the urease enzyme itself is antigenic, activates the host immune system, and indirectly produces injury by stimulating inflammatory cells [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial phospholipases can alter the phospholipid content of the gastric mucosal barrier, changing its surface tension, hydrophobicity, and permeability [<a href="#rid19">19</a>]. The conversion of lecithin to lysolecithin (a toxic compound) by phospholipase A2 can lead to cell injury [<a href="#rid19">19</a>], while lipolysis can disrupt the structure and integrity of gastric mucus [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori</em> produces more catalase enzyme than most other bacteria. This enzyme, an antioxidant, may protect the organism from toxic oxygen metabolites liberated by activated neutrophils and allow it to survive and proliferate in an inflamed and damaged gastric mucosa [<a href="#rid19">19,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial proteolytic enzyme activity can further degrade mucus. However, the importance of proteolysis remains controversial [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Bacterial strain differences</span><span class="headingEndMark"> — </span>Functional differences exist between strains of <em>H. pylori</em> that may relate to virulence and tissue damage [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H6"><span class="h3">CagA and VacA</span><span class="headingEndMark"> — </span>One such difference is expression of an 87 kilodalton (kd) vacuolating cytotoxin (VacA) which causes cell injury in vitro and gastric tissue damage in vivo [<a href="#rid22">22-24</a>]. All <em>H. pylori</em> contain the gene coding for VacA; however, only those strains that encode the cytotoxin-associated gene (cag) pathogenicity island (PAI), including cytotoxin-associated gene A (CagA), coding for a 128 to 140 kd protein (CagA), coexpress VacA [<a href="#rid23">23</a>]. VacA behaves as a passive urea transporter that is potentially capable of increasing the permeability of the gastric epithelium to urea, thereby creating a favorable environment for <em>H. pylori</em> infectivity [<a href="#rid25">25</a>]. Virulence of VacA appears to depend upon the function of a tyrosine phosphatase receptor in gastric epithelial cells [<a href="#rid26">26</a>]. <em>H. pylori</em> strains with different VacA alleles have differing toxicity [<a href="#rid27">27</a>].</p><p>CagA is not cytotoxic but is antigenic and can be detected serologically [<a href="#rid28">28</a>]. Its function is unknown but, since it is necessary for VacA expression, it may play a role in transcription, excretion, or function of the VacA cytotoxin [<a href="#rid28">28</a>]. <em>H. pylori</em> can translocate its CagA protein into gastric epithelial cells via a type IV secretory apparatus. There it is tyrosine phosphorylated and possibly plays a role in host cell responses [<a href="#rid29">29-31</a>].</p><p>Virulent strains of <em>H. pylori</em> encode cag PAI, which expresses a type IV secretion system (T4SS). This T4SS forms a syringe-like pilus structure for the injection of virulence factors such as the CagA effector protein into host target cells. This is achieved by a number of T4SS proteins, including CagI, CagL, CagY and CagA, which by itself binds the host cell integrin member β(1) followed by delivery of CagA across the host cell membrane. CagA is not cytotoxic but is antigenic and can be detected serologically [<a href="#rid28">28</a>]. A role of CagA interaction with phosphatidylserine has also been shown to be important for the injection process. After delivery, CagA becomes phosphorylated by oncogenic tyrosine kinases and mimics a host cell factor for the activation or inactivation of some specific intracellular signalling pathways [<a href="#rid28">28-32</a>]. </p><p>Strains producing VacA and CagA cause more intense tissue inflammation and induce cytokine production [<a href="#rid23">23,24,33</a>]. Two other genes (picA and picB, now termed CagE) which are cotranscribed and genetically linked to cagA share homology with genes coding for toxins in other known pathogenic bacteria [<a href="#rid23">23,34</a>]. The gene product of picB (CagE) induces the release of epithelial cytokines, including interleukin-8 (IL-8) [<a href="#rid23">23,34</a>]. This effect appears to be mediated by nuclear factor kappa B, which activates transcription of IL-8 MRNA [<a href="#rid35">35</a>]. In addition, bacteria that express CagA are potent inducers of IL-8 [<a href="#rid36">36,37</a>].</p><p>The clinical significance of CagA positivity is demonstrated in two different disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 85 to 100 percent of patients with duodenal ulcers have CagA+ strains, compared to 30 to 60 percent of infected patients who do not develop ulcers [<a href="#rid38">38</a>]. Cag E positivity has also been associated with gastroduodenal disease in adults and children [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CagA strains are associated with a higher frequency of precancerous lesions and gastric cancer [<a href="#rid41">41</a>]. The risk of malignancy may be related to specific amino acid sequences (EPIYA) in the CagA protein [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p></p><p class="headingAnchor" id="H23985291"><span class="h3">Other virulence factors</span><span class="headingEndMark"> — </span>In addition to CagA, several other <em>H. pylori</em> virulence factors have been described [<a href="#rid43">43-49</a>]. The strength of these associations has not been well defined in large populations.</p><p class="bulletIndent1"><span class="glyph">●</span>"Induced by contact with epithelium" (iceA) has been associated with peptic ulcers [<a href="#rid43">43,46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Blood group antigen-binding adhesin" (babA2) has been associated with duodenal ulcers and gastric cancer [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Outer inflammatory protein" (oipA) has been associated with duodenal ulcers [<a href="#rid49">49</a>].</p><p></p><p>Many of the virulence factors described above can coexist in the same <em>H. pylori</em> strains, making it unclear as to which factors might be most important. In addition, as noted above, expression of CagA is associated with both gastric cancer and duodenal ulcer, yet these two disorders rarely, if ever, coexist thereby minimizing the significance of this "virulence factor" in understanding disease pathogenesis.</p><p>One study suggested that the oipA status may be a better predictor of <em>H. pylori</em> virulence than any of the other previously described virulence factors. The study included 247 <em>H. pylori</em> infected patients (86 with gastritis, 86 with a duodenal ulcer, and 75 with gastric carcinoma) in whom <em>H. pylori</em> isolates were tested for the other <em>H. pylori</em> virulence factors discussed above. On multivariate analysis, only oipA status remained an independent predictor of <em>H. pylori</em> density, mucosal inflammation, and high mucosal IL-8 levels. However, the actual biological significance of these observations is unknown. Adaptation to gastric conditions is enabled by phase variation of genes encoding outer membrane proteins [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H8"><span class="h1">INFLAMMATORY RESPONSE</span><span class="headingEndMark"> — </span>Although <em>H. pylori</em> is a noninvasive organism, it stimulates a robust inflammatory and immune response [<a href="#rid52">52,53</a>]. A variety of factors may contribute to these changes, which are described below. Bacterial colonization, persistence and virulence, and resulting innate and adaptive host immune responses are all important in the pathogenesis of <em>H. pylori</em> related disease [<a href="#rid7">7,54,55</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The organism produces a number of antigenic substances, including heat shock protein, urease, and lipopolysaccharide, all of which can be taken up and processed by lamina propria macrophages and activate T-cells [<a href="#rid53">53,56</a>]. Cellular disruption, especially adjacent to epithelial tight junctions, undoubtedly enhances antigen presentation to the lamina propria and facilitates immune stimulation. The net result is increased production of inflammatory cytokines such as IL-1, IL-6, tumor necrosis factor-alpha (TNF-alpha), and most notably, IL-8 [<a href="#rid36">36,52,57,58</a>]. (See <a class="local">'Interleukin-8 and other cytokines'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A B cell response to <em>H. pylori </em>(with production of IgG and IgA antibodies) occurs locally in the gastroduodenal mucosa and systemically. The role of local antibodies in producing tissue injury or modulating inflammation in <em>H. pylori</em> infection remains controversial [<a href="#rid52">52,53</a>]. Prolonged stimulation of gastric B cells by activated T cells can lead to MALT lymphoma in rare cases. (See  <a class="medical medical_review" href="/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p></p><p>T cells are also activated during infection and their cytokines boost bacterial binding (by inducing class II MHC). While T cells are recruited to the infected gastric mucosa, they appear to be hyporesponsive. B7-H1 (programmed death-1 ligand 1), a member of B7 family of proteins associated with T cell inhibition, appears to be involved in the suppression of T cell proliferation and IL-2 synthesis during <em>H. pylori</em> infection, and thus may contribute to its chronicity [<a href="#rid59">59</a>].</p><p>Different T helper cell subsets can be distinguished by characteristic profiles of cytokine secretion. Th1 cells promote cell-mediated immune responses through elaboration of TNF-alpha and IFN gamma. Th2 cells produce Il-4, IL-10 and TGF beta. It appears that during <em>H. pylori</em> infection the T-cell immunity is inappropriately skewed toward a Th1 response that promotes epithelial cell inflammatory cytokine production (IL-8 stimulated by IFN gamma and TNF-alpha) and directly impacts epithelial apoptosis [<a href="#rid60">60,61</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori</em> infection induces a marked increase in the flux of leukocytes and in the appearance of platelet and leukocyte-platelet aggregates in gastric venules in a murine model [<a href="#rid62">62</a>]. Circulating platelet aggregates and activated platelets were also detected in patients infected with <em>H. pylori</em>, suggesting that platelet activation and aggregation contribute to the associated microvascular dysfunction and inflammatory cell recruitment. Platelet aggregation mediated by an <em>H. pylori</em> interaction with von Willebrand factor is speculated to contribute to infection related ulcer disease but also possibly non-GI manifestations of infection such as cardiovascular disease and idiopathic thrombocytopenia [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not all <em>H. pylori</em> infected individuals develop clinical disease. Host genetics are important in determining the physiologic and clinical response to infection [<a href="#rid65">65</a>]. Host polymorphism of IL-1 beta (and possibly IL-10) appears to determine the degree of inflammatory response to infection, resulting alteration in acid secretion (hyper or hypo secretion), and risk for subsequent gastric cancer [<a href="#rid66">66,67</a>]. One series of meta-analyses investigated genes coding for the interleukin (IL) proteins (IL1B, IL1RN, IL8, and IL10) and for TNF-alpha. Gastric cancers were stratified by histologic subtype and anatomic subsite, by <em>H. pylori</em> infection status, by geographic location (Asian or non-Asian study population), and by a quantitative index of study quality. Results consistently supported increased cancer risk for IL1RN2 carriers; the increased risk was specific to non-Asian populations and was seen for intestinal and diffuse cancers, distal cancers, and, to a lesser extent, cardia cancers. In Asian populations, reduced risk was observed in association with IL1B-31C carrier status. These results indicate the importance of stratification by anatomic site, histologic type, <em>H. pylori</em> infection, and country of origin. Study quality considerations, both laboratory and epidemiologic, can also affect results and may explain, in part, the variability in results published to date [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Interleukin-8 and other cytokines</span><span class="headingEndMark"> — </span>Research has centered on epithelial IL-8 production induced by different strains of <em>H. pylori</em> [<a href="#rid36">36,69</a>]. IL-8 is a potent chemotactic factor, activates neutrophils, and recruits acute inflammatory cells into the mucosa. <em>H. pylori</em> appears to activate transcription factor NF-kB (nuclear factor kappa B), which in turn increases IL-8 production [<a href="#rid35">35,70</a>]. NF-kB also regulates the expression of additional inflammatory response genes, and may play a role in the mucosal epithelial response to other bacterial infections in addition to <em>H. pylori</em>.</p><p>Bacteria that express CagA and VacA are more potent inducers of IL-8; however, the gene primarily responsible for IL-8 induction is picB (now renamed CagE), which is located upstream of the CagA gene [<a href="#rid34">34</a>]. CagA/VacA-positive strains are also more often found in patients with clinical manifestations of <em>H. pylori</em> infection, indirectly suggesting that IL-8 may play an important pathophysiologic role in gastroduodenal disease.</p><p>TNF-alpha can also augment IL-8 production by the inflamed mucosa. Following successful eradication of <em>H. pylori</em>, mucosal levels of mRNA for both TNF-alpha and IL-8 are reduced in parallel with the decline in local inflammation [<a href="#rid71">71</a>].</p><p><em>H. pylori</em> infection increases IL-17 in the gastric mucosa of humans and experimental animals. IL-17 induces the secretion of IL-8 by activating the ERK 1/2 MAP kinase pathway. IL-23 is also increased in patients with <em>H. pylori</em> related gastritis and regulates IL-17 secretion via the STAT3 pathway. The early events in the immune response of immunized and challenged mice include the recruitment of T cells and the production of IL-17. Neutrophil attracting chemokines are released, and the bacterial load is considerably reduced [<a href="#rid72">72</a>]. IL-17 plays a dual role in infection and vaccination. In infection, T regulatory cells (Tregs) suppress the inflammatory reaction driven by IL-17, thereby favoring bacterial persistence. Immunization produces Helicobacter-specific memory T-helper cells that can possibly alter the ratio between T-helper 17 and Treg responses so that the IL-17-driven inflammatory reaction can overcome the Treg response leading to bacterial clearance [<a href="#rid72">72</a>].</p><p>Virulent <em>H. pylori</em> strains that specifically activate signaling in epithelial cells via the innate immune molecule, nucleotide oligomerization domain 1 (NOD1), are more frequently associated with IFN-gamma-dependent inflammation and with severe clinical outcomes (ie, gastric cancer and peptic ulceration). <em>H. pylori</em> activation of the NOD1 pathway causes enhanced proinflammatory signaling in epithelial cells in response to IFN-gamma stimulation through the direct effects of <em>H. pylori</em> on two components of the IFN-gamma signaling pathway, STAT1 and IFN regulatory factor 1 (IRF1) [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Survival of H. pylori</span><span class="headingEndMark"> — </span><em>H. pylori</em> itself is in part able to survive this inflammatory onslaught by producing the enzyme, catalase. This enzyme neutralizes the damaging reactive oxygen metabolites liberated by neutrophils [<a href="#rid19">19</a>]. With time, the host appears to downregulate the acute inflammatory response, making it easier for the organism to persist and proliferate [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H11"><span class="h1">ANTIBODY RESPONSE</span><span class="headingEndMark"> — </span>Most infected individuals systemically produce specific antibodies to a variety of <em>H. pylori</em> antigens. The antibody response changes as infection progresses from an acute to a chronic stage [<a href="#rid75">75</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Detection of IgM antibodies is an insensitive indicator of acute infection and generally is not clinically useful, even in children [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgA and IgG antibodies are produced in response to infection, remain present as long as infection is active, and quantitatively decrease after infection is cured [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to CagA protein are detectable in gastric tissue and serum and permit the identification of infection with presumably more virulent organisms [<a href="#rid78">78</a>].</p><p></p><p>The role of local antibodies in the immunopathogenesis of gastroduodenal mucosal injury is unclear [<a href="#rid52">52</a>]. Virtually all infected persons have a specific gastric mucosal IgA and IgG response. IgA antibodies may modulate mucosal injury by inhibiting antigen uptake, disrupting bacterial adherence and motility, and neutralizing various toxins. IgG presumably augments inflammatory injury by activating complement and facilitating neutrophil activation.</p><p>An antibody response may also be seen against autoantigens, including IL-8 [<a href="#rid79">79</a>], antral epithelium [<a href="#rid80">80,81</a>], and homologous host and bacterial epitopes (eg, LewisX, lipopolysaccharide, and heat shock protein) [<a href="#rid52">52</a>]. The immunoglobulin specificity of MALT lymphoma may be for such autoantigens [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H12"><span class="h1">VACCINATION</span><span class="headingEndMark"> — </span>While the mucosal immune response to <em>H. pylori</em> leads to tissue injury, it is also key to vaccination strategies [<a href="#rid72">72,83,84</a>]. One could question if effective vaccination is possible since the organism can successfully evade the immune response to natural infection [<a href="#rid85">85</a>]. Nevertheless, preliminary studies suggest that preventive vaccination may be feasible. Immunization with crude sonicates of bacteria [<a href="#rid86">86,87</a>] and recombinant subunits of urease [<a href="#rid88">88,89</a>] and catalase [<a href="#rid90">90</a>] protect animals from <em>H. pylori</em> exposure. Human vaccines have undergone [<a href="#rid89">89,91</a>] and continue to undergo clinical testing [<a href="#rid92">92</a>]. In a randomized phase 3 vaccine trial, 4464 <em>H. pylori</em> uninfected children (ages 6 to 15 years) were assigned to a three-dose oral recombinant <em>H. pylori</em> vaccine or placebo [<a href="#rid93">93</a>]. The vaccine contained fusion proteins composed of the B subunits of <em>H. pylori</em> urease and heat-labile toxin of <em>Escherichia coli. </em>At one year, the incidence of <em>H. pylori</em> infection was significantly lower in the vaccine group as compared with placebo (0.7 versus 2.4 events per 100 person-years), with a vaccine efficacy of 72 percent (95% CI 48.2-85.6). Among patients who completed extended follow-up, <em>H. pylori</em> acquisition continued to be lower in vaccinated as compared with unvaccinated children, but protection levels were lower in the second and third year (vaccine efficacy 55 [95% CI 0.9-81.0] and 56 [95% CI -24.7-86.2] percent, respectively). There were no serious adverse events related to the vaccine. Additional studies with long-term follow-up are needed to validate these results.</p><p>Studies on vaccination have expanded to the area of therapeutic immunization [<a href="#rid85">85,94</a>]. A therapeutic vaccine could boost the natural immune response and facilitate spontaneous bacterial eradication or enhance the effectiveness of antibiotic regimens. A successful therapeutic vaccine would obviate the widespread use of antibiotics and minimize the development of antibiotic-resistant <em>H. pylori</em> organisms. Unfortunately, the promise of vaccines has not been met after more than two decades of research. A renewed or expanded commitment to exploit advances in our understanding of the host immune response to <em>H. pylori</em> is necessary for the advancement of an <em>H. pylori</em> vaccine [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The pathophysiology of <em>H. pylori</em> infection and its eventual clinical outcome should be viewed as a complex interaction between the host and the bacterium. This interaction is influenced by the environment and modulated by a number of largely as yet unidentified factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tissue injury induced by <em>H. pylori </em>depends upon bacterial attachment and the subsequent release of enzymes and other microbial products that can cause cellular damage. (See <a class="local">'Bacterial factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional differences exist between strains of <em>H. pylori</em> that may relate to virulence and tissue damage. However, many of the virulence factors can coexist in the same <em>H. pylori</em> strains, making it unclear as to which factors might be most important. (See <a class="local">'Bacterial strain differences'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although <em>H. pylori</em> is a noninvasive organism, it stimulates a robust inflammatory and immune response. Bacterial colonization, persistence and virulence, and resulting innate and adaptive host immune responses are all important in the pathogenesis of <em>H. pylori</em> related disease. (See <a class="local">'Inflammatory response'</a> above.)</p><p></p><p class="headingAnchor" id="H1145626789"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347:1175.</a></li><li><a class="nounderline abstract_t">Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006; 130:188.</a></li><li><a class="nounderline abstract_t">Logan RP. Adherence of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10 Suppl 1:3.</a></li><li><a class="nounderline abstract_t">Dytoc M, Gold B, Louie M, et al. Comparison of Helicobacter pylori and attaching-effacing Escherichia coli adhesion to eukaryotic cells. Infect Immun 1993; 61:448.</a></li><li><a class="nounderline abstract_t">Noach LA, Rolf TM, Tytgat GN. Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa. J Clin Pathol 1994; 47:699.</a></li><li><a class="nounderline abstract_t">Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996; 93:14648.</a></li><li><a class="nounderline abstract_t">Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19:449.</a></li><li><a class="nounderline abstract_t">Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279:373.</a></li><li><a class="nounderline abstract_t">Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 2000; 97:7533.</a></li><li><a class="nounderline abstract_t">Mahdavi J, Sondén B, Hurtig M, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297:573.</a></li><li><a class="nounderline abstract_t">Sakamoto S, Watanabe T, Tokumaru T, et al. Expression of Lewisa, Lewisb, Lewisx, Lewisy, siayl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res 1989; 49:745.</a></li><li><a class="nounderline abstract_t">Moran AP. The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Aliment Pharmacol Ther 1996; 10 Suppl 1:39.</a></li><li><a class="nounderline abstract_t">Wang G, Ge Z, Rasko DA, Taylor DE. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. Mol Microbiol 2000; 36:1187.</a></li><li><a class="nounderline abstract_t">Fan X, Crowe SE, Behar S, et al. The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage. J Exp Med 1998; 187:1659.</a></li><li><a class="nounderline abstract_t">Fan X, Gunasena H, Cheng Z, et al. Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol 2000; 165:1918.</a></li><li><a class="nounderline abstract_t">Cullen TW, Giles DK, Wolf LN, et al. Helicobacter pylori versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa. PLoS Pathog 2011; 7:e1002454.</a></li><li><a class="nounderline abstract_t">Hu LT, Mobley HL. Purification and N-terminal analysis of urease from Helicobacter pylori. Infect Immun 1990; 58:992.</a></li><li><a class="nounderline abstract_t">Mobley HL. The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Aliment Pharmacol Ther 1996; 10 Suppl 1:57.</a></li><li><a class="nounderline abstract_t">Nilius M, Malfertheiner P. Helicobacter pylori enzymes. Aliment Pharmacol Ther 1996; 10 Suppl 1:65.</a></li><li><a class="nounderline abstract_t">Slomiany BL, Kasinathan C, Slomiany A. Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol). Am J Gastroenterol 1989; 84:1273.</a></li><li class="breakAll">Hazell SL. Urease and catalase as virulence factors of Helicobacter pylori. In: Helicobacter pylori 1990, Menge H, Gregor M, Tytgat GN, et al (Eds), Springer Verlag, Berlin 1991.</li><li><a class="nounderline abstract_t">Mobley HL. Defining Helicobacter pylori as a pathogen: strain heterogeneity and virulence. Am J Med 1996; 100:2S.</a></li><li><a class="nounderline abstract_t">Blaser MJ. Role of vacA and the cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996; 10 Suppl 1:73.</a></li><li><a class="nounderline abstract_t">Figura N. Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection. Aliment Pharmacol Ther 1996; 10 Suppl 1:79.</a></li><li><a class="nounderline abstract_t">Tombola F, Morbiato L, Del Giudice G, et al. The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 2001; 108:929.</a></li><li><a class="nounderline abstract_t">Fujikawa A, Shirasaka D, Yamamoto S, et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 2003; 33:375.</a></li><li><a class="nounderline abstract_t">Letley DP, Rhead JL, Twells RJ, et al. Determinants of non-toxicity in the gastric pathogen Helicobacter pylori. J Biol Chem 2003; 278:26734.</a></li><li><a class="nounderline abstract_t">Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993; 90:5791.</a></li><li><a class="nounderline abstract_t">Jenks PJ, Kusters JG. Pathogenesis and virulence factors of Helicobacter pylori. Curr Opin Gastroenterol 2000; 16:s11.</a></li><li><a class="nounderline abstract_t">Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295:683.</a></li><li><a class="nounderline abstract_t">Naumann M. Pathogenicity island-dependent effects of Helicobacter pylori on intracellular signal transduction in epithelial cells. Int J Med Microbiol 2005; 295:335.</a></li><li><a class="nounderline abstract_t">Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J 2011; 278:1190.</a></li><li><a class="nounderline abstract_t">Spechler SJ, Fischbach L, Feldman M. Clinical aspects of genetic variability in Helicobacter pylori. JAMA 2000; 283:1264.</a></li><li><a class="nounderline abstract_t">Tummuru MK, Sharma SA, Blaser MJ. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 1995; 18:867.</a></li><li><a class="nounderline abstract_t">Covacci A, Rappuoli R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 2000; 191:587.</a></li><li><a class="nounderline abstract_t">Yamaoka Y, Kita M, Kodama T, et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996; 110:1744.</a></li><li><a class="nounderline abstract_t">Yamaoka Y, Kita M, Kodama T, et al. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997; 41:442.</a></li><li><a class="nounderline abstract_t">Weel JF, van der Hulst RW, Gerrits Y, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996; 173:1171.</a></li><li><a class="nounderline abstract_t">Day AS, Jones NL, Lynett JT, et al. cagE is a virulence factor associated with Helicobacter pylori-induced duodenal ulceration in children. J Infect Dis 2000; 181:1370.</a></li><li><a class="nounderline abstract_t">Fallone CA, Barkun AN, Göttke MU, et al. Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J Gastroenterol 2000; 95:659.</a></li><li><a class="nounderline abstract_t">Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125:1636.</a></li><li><a class="nounderline abstract_t">Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135:91.</a></li><li><a class="nounderline abstract_t">van Doorn LJ, Figueiredo C, Sanna R, et al. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 1998; 115:58.</a></li><li><a class="nounderline abstract_t">Atherton JC, Cao P, Peek RM Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270:17771.</a></li><li><a class="nounderline abstract_t">Atherton JC, Peek RM Jr, Tham KT, et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112:92.</a></li><li><a class="nounderline abstract_t">Peek RM Jr, Thompson SA, Donahue JP, et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. Proc Assoc Am Physicians 1998; 110:531.</a></li><li><a class="nounderline abstract_t">Nogueira C, Figueiredo C, Carneiro F, et al. Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 2001; 158:647.</a></li><li><a class="nounderline abstract_t">Gerhard M, Lehn N, Neumayer N, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999; 96:12778.</a></li><li><a class="nounderline abstract_t">Yamaoka Y, Kikuchi S, el-Zimaity HM, et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123:414.</a></li><li><a class="nounderline abstract_t">Xu C, Soyfoo DM, Wu Y, Xu S. Virulence of Helicobacter pylori outer membrane proteins: an updated review. Eur J Clin Microbiol Infect Dis 2020; 39:1821.</a></li><li><a class="nounderline abstract_t">Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter 2010; 15 Suppl 1:14.</a></li><li><a class="nounderline abstract_t">Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther 1996; 10 Suppl 1:29.</a></li><li><a class="nounderline abstract_t">Ernst PB, Jin Y, Reyes VE, Crowe SE. The role of the local immune response in the pathogenesis of peptic ulcer formation. Scand J Gastroenterol Suppl 1994; 205:22.</a></li><li><a class="nounderline abstract_t">Portal-Celhay C, Perez-Perez GI. Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clin Sci (Lond) 2006; 110:305.</a></li><li><a class="nounderline abstract_t">Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 2008; 57:1375.</a></li><li><a class="nounderline abstract_t">Di Tommaso A, Xiang Z, Bugnoli M, et al. Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies. Infect Immun 1995; 63:1102.</a></li><li><a class="nounderline abstract_t">Fan XG, Chua A, Fan XJ, Keeling PW. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995; 48:133.</a></li><li><a class="nounderline abstract_t">Crowe SE, Alvarez L, Dytoc M, et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995; 108:65.</a></li><li><a class="nounderline abstract_t">Das S, Suarez G, Beswick EJ, et al. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 2006; 176:3000.</a></li><li><a class="nounderline abstract_t">Elliott SN, Ernst PB, Kelly CP. The year in Helicobacter pylori 2001: Molecular inflammation. Curr Opin Gastroenterol Suppl 2001; 17:S12.</a></li><li><a class="nounderline abstract_t">Wang J, Brooks EG, Bamford KB, et al. Negative selection of T cells by Helicobacter pylori as a model for bacterial strain selection by immune evasion. J Immunol 2001; 167:926.</a></li><li><a class="nounderline abstract_t">Elizalde JI, Gómez J, Panés J, et al. Platelet activation In mice and human Helicobacter pylori infection. J Clin Invest 1997; 100:996.</a></li><li><a class="nounderline abstract_t">Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003; 124:1846.</a></li><li><a class="nounderline abstract_t">Handin RI. A hitchhiker's guide to the galaxy--an H. pylori travel guide. Gastroenterology 2003; 124:1983.</a></li><li><a class="nounderline abstract_t">Usui Y, Taniyama Y, Endo M, et al. Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. N Engl J Med 2023; 388:1181.</a></li><li><a class="nounderline abstract_t">El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398.</a></li><li><a class="nounderline abstract_t">El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut 2001; 48:743.</a></li><li><a class="nounderline abstract_t">Persson C, Canedo P, Machado JC, et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 2011; 173:259.</a></li><li><a class="nounderline abstract_t">Crabtree JE, Covacci A, Farmery SM, et al. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol 1995; 48:41.</a></li><li><a class="nounderline abstract_t">Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997; 113:1099.</a></li><li><a class="nounderline abstract_t">Moss SF, Legon S, Davies J, Calam J. Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 1994; 35:1567.</a></li><li><a class="nounderline abstract_t">Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter 2011; 16:1.</a></li><li><a class="nounderline abstract_t">Allison CC, Ferrand J, McLeod L, et al. Nucleotide oligomerization domain 1 enhances IFN-γ signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity. J Immunol 2013; 190:3706.</a></li><li><a class="nounderline abstract_t">Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102:720.</a></li><li><a class="nounderline abstract_t">Mitchell HM, Hazell SL, Kolesnikow T, et al. Antigen recognition during progression from acute to chronic infection with a cagA-positive strain of Helicobacter pylori. Infect Immun 1996; 64:1166.</a></li><li><a class="nounderline abstract_t">Blecker U, Lanciers S, Hauser B, et al. The contribution of specific immunoglobulin M antibodies to the diagnosis of Helicobacter pylori infection in children. Eur J Gastroenterol Hepatol 1995; 7:979.</a></li><li><a class="nounderline abstract_t">Kosunen TU. Antibody titres in Helicobacter pylori infection: implications in the follow-up of antimicrobial therapy. Ann Med 1995; 27:605.</a></li><li><a class="nounderline abstract_t">Cover TL, Glupczynski Y, Lage AP, et al. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995; 33:1496.</a></li><li><a class="nounderline abstract_t">Crabtree JE, Peichl P, Wyatt JI, et al. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993; 37:65.</a></li><li><a class="nounderline abstract_t">Negrini R, Lisato L, Zanella I, et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 1991; 101:437.</a></li><li><a class="nounderline abstract_t">Negrini R, Savio A, Appelmelk BJ. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 1997; 2 Suppl 1:S13.</a></li><li><a class="nounderline abstract_t">Greiner A, Marx A, Heesemann J, et al. Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. Lab Invest 1994; 70:572.</a></li><li><a class="nounderline abstract_t">Sutton P, Lee A. Review article: Helicobacter pylori vaccines-the current status. Aliment Pharmacol Ther 2000; 14:1107.</a></li><li><a class="nounderline abstract_t">Blanchard TG, Czinn SJ. Immunology of Helicobacter pylori and prospects for vaccine. Gastroenterol Clin North Am 2000; 29:671.</a></li><li><a class="nounderline abstract_t">Crabtree JE. Eradication of chronic Helicobacter pylori infection by therapeutic vaccination. Gut 1998; 43:7.</a></li><li><a class="nounderline abstract_t">Lee A, Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 1994; 62:3594.</a></li><li><a class="nounderline abstract_t">Marchetti M, Aricò B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267:1655.</a></li><li><a class="nounderline abstract_t">Ferrero RL, Thiberge JM, Huerre M, Labigne A. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun 1994; 62:4981.</a></li><li><a class="nounderline abstract_t">Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116:804.</a></li><li><a class="nounderline abstract_t">Radcliff FJ, Hazell SL, Kolesnikow T, et al. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 1997; 65:4668.</a></li><li><a class="nounderline abstract_t">Kreiss C, Buclin T, Cosma M, et al. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996; 347:1630.</a></li><li><a class="nounderline abstract_t">Malfertheiner P, Schultze V, Rosenkranz B, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008; 135:787.</a></li><li><a class="nounderline abstract_t">Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386:1457.</a></li><li><a class="nounderline abstract_t">Corthésy-Theulaz I, Porta N, Glauser M, et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995; 109:115.</a></li><li><a class="nounderline abstract_t">Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2011; 8:133.</a></li></ol></div><div id="topicVersionRevision">Topic 15 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374879" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401482" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The translation of Helicobacter pylori basic research to patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730255" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adherence of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380793" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of Helicobacter pylori and attaching-effacing Escherichia coli adhesion to eukaryotic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962619" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962108" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847081" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pathogenesis of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430586" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852959" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142529" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910493" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Expression of Lewisa, Lewisb, Lewisx, Lewisy, siayl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730258" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The role of lipopolysaccharide in Helicobacter pylori pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931272" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lewis antigens in Helicobacter pylori: biosynthesis and phase variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9584144" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10925273" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22216004" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Helicobacter pylori versus the host: remodeling of the bacterial outer membrane is required for survival in the gastric mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2318539" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Purification and N-terminal analysis of urease from Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730260" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730261" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Helicobacter pylori enzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2801678" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2801678" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644779" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Defining Helicobacter pylori as a pathogen: strain heterogeneity and virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730262" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Role of vacA and the cagA locus of Helicobacter pylori in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730263" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560962" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598897" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738773" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Determinants of non-toxicity in the gastric pathogen Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8516329" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pathogenesis and virulence factors of Helicobacter pylori</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743164" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173500" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pathogenicity island-dependent effects of Helicobacter pylori on intracellular signal transduction in epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352489" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10714712" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical aspects of genetic variability in Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8825091" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10684850" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964399" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391240" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8627069" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762568" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : cagE is a virulence factor associated with Helicobacter pylori-induced duodenal ulceration in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710054" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724815" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Meta-analysis of the relationship between cagA seropositivity and gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474244" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9649459" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629077" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978347" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824536" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159201" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Helicobacter pylori genotypes may determine gastric histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10535999" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145793" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32557327" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Virulence of Helicobacter pylori outer membrane proteins: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054648" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pathogenesis of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730257" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gastric mucosal inflammatory responses to Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7863238" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The role of the local immune response in the pathogenesis of peptic ulcer formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16464172" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18467372" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7868233" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7745112" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7806065" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16493058" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The year in Helicobacter pylori 2001: Molecular inflammation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11441100" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Negative selection of T cells by Helicobacter pylori as a model for bacterial strain selection by immune evasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9276716" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Platelet activation In mice and human Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12806618" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12806635" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A hitchhiker's guide to the galaxy--an H. pylori travel guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36988593" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10746728" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Interleukin-1 polymorphisms associated with increased risk of gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11358884" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The importance of interleukin 1beta in Helicobacter pylori associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21178102" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7706517" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9322504" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828974" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cytokine gene expression in Helicobacter pylori associated antral gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21241406" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The role of interleukin-17 in the Helicobacter pylori induced infection and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460743" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Nucleotide oligomerization domain 1 enhances IFN-γsignaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732141" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606074" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Antigen recognition during progression from acute to chronic infection with a cagA-positive strain of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8590145" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The contribution of specific immunoglobulin M antibodies to the diagnosis of Helicobacter pylori infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541040" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antibody titres in Helicobacter pylori infection: implications in the follow-up of antimicrobial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7650174" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Serologic detection of infection with cagA+ Helicobacter pylori strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418474" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2065920" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9432348" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Autoantibodies to gastric mucosa in Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176897" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971226" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Review article: Helicobacter pylori vaccines-the current status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030080" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Immunology of Helicobacter pylori and prospects for vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771398" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Eradication of chronic Helicobacter pylori infection by therapeutic vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039937" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7886456" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Development of a mouse model of Helicobacter pylori infection that mimics human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7927778" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092302" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9353048" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Catalase, a novel antigen for Helicobacter pylori vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8667902" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18619971" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142048" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797009" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21304478" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Vaccinating against Helicobacter pylori infection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
